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Sir,
We would like to thank the authors of the above letter for
providing more recent information than our own. Our treatment
pattern survey was carried out in 2001. It aimed to provide no
more than a snap-shot of treatments used and treatment costs, and
identify the trends that may lead to further cost increases. All three
points noted by Jimeno and co-workers were discussed in our
article as potential factors driving costs even higher.
Firstly, as discussed by Jimeno et al, the difference in
incidence of initially metastatic breast cancer (IMBC) may be
explained by the different data sources of the two studies. Our
incidence figures were based on information from cancer
registries, but registry databases do not include all patients with
cancer, nor do they have complete staging information for every
registered patient.
Secondly, survival with IMBC is highly variable, ranging from a
few months to several years. Several studies indicate that survival
is influenced by the sites of metastasis. Other factors such as time
of diagnosis, availability of treatments and local treatment patterns
may also have an impact as well as chance. The Royal Marsden
Hospital data set used in our analysis contains information on over
2300 female patients with metastatic breast cancer vs the 370
patients in the study by Jimeno and co-workers, and was deemed a
very reliable data source.
Lastly, treatment patterns change across countries and through
time. As mentioned before, our resource use survey provided a
snap-shot of treatments used in the UK in 2001. Since then, use of
trastuzumab, the taxanes and aromotase inhibitors increased, and
the costs are likely to increase further as their role in therapy
continues to grow.
We agree with Jimeno and co-workers that metastatic breast
cancer imposes a substantial economic burden, and this burden is
likely to increase as the relatively more expensive treatments
become more widely available.
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